Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 4Unknown 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1

Conditions

Small Cell Lung Carcinoma 1Neoplasm, Residual 1NSCLC 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 333Radiotherapy 315Cyclophosphamide 295pembrolizumab 282Cisplatin 266Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 206Bevacizumab 187Gemcitabine 177venetoclax 172Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Nivolumab 156Paclitaxel 155Standard of Care 137Surveys and Questionnaires 131Surgical Procedures, Operative 130Dexamethasone 127Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER × sugemalimab × Clear all
NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Sichuan University

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Peking Union Medical College

Phase NA Recruiting
150 enrolled
Thoracic

NSCLC

NCT05623267 2023-08-07

SURPASS

Sun Yat-sen University

Phase 2/3 Recruiting
346 enrolled
Tumor-Agnostic

Neoplasm, Residual

NCT05940532 2023-07-11

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

Hunan Cancer Hospital

Phase 2 Recruiting
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡